KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro (scientific article published on 23 December 2013)

A randomized, parallel study of the safety and efficacy of 45 mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide-responsive uncomplicated falciparum malaria [ISCRTN50134587].

Q25255678

Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging

Q27335248

Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery

Q27861956

Plasmodium falciparum PF10_0164 (ETRAMP10.3) is an essential parasitophorous vacuole and exported protein in blood stages

Q27973895

Plasmodium vivax polymorphism in a clinical drug trial

Q28347253

Studies on the prophylactic and radical curative activity of RC-12 against Plasmodium cynomolgi in Macaca mulatta

Q28363642

Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery

Q28477602

The neglected burden of Plasmodium vivax malaria

Q29618450

Vivax malaria: neglected and not benign

Q29619167

Resistance to therapies for infection by Plasmodium vivax

Q33481576

Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects

Q33613720

Enzymatic deficiency in primaquine-sensitive erythrocytes

Q33969317

Imidazolopiperazines: lead optimization of the second-generation antimalarial agents

Q34270117

Plasmodium vivax: clinical spectrum, risk factors and pathogenesis

Q34314662

The global distribution and population at risk of malaria: past, present, and future

Q34548302

Activation of the hypnozoite: a part of Plasmodium vivax life cycle and survival

Q34915774

Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta)

Q35181605

Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations

Q35576016

Use of non-human primate hepatocytes for in vitro study of the pre-erythrocytic stages of malaria parasites

Q36668498

Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate

Q36702987

In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen

Q36736936

Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand

Q36868308

Statistical model to evaluate in vivo activities of antimalarial drugs in a Plasmodium cynomolgi-macaque model for Plasmodium vivax malaria

Q37072009

Atovaquone and proguanil hydrochloride for prophylaxis of malaria

Q38097805

Primaquine resistance in Plasmodium vivax

Q38950998

Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures

Q38969741

Tertian malaria (Plasmodium vivax and Plasmodium ovale) in two travelers despite atovaquone-proguanil prophylaxis

Q39107157

Imidazolopiperazines: hit to lead optimization of new antimalarial agents.

Q39530026

Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes

Q41946006

In vitro activity of antimalarial compounds on the exoerythrocytic stages of Plasmodium cynomolgi and P. knowlesi

Q41946095

Synthesis and antimalarial activity of 2-guanidino-4-oxoimidazoline derivatives

Q42733266

Complete development of hepatic stages of Plasmodium falciparum in vitro

Q44487027

Preliminary report of the evaluation of the gametocytocidal action of bulaquine, in adult patients with acute, Plasmodium falciparum malaria

Q44981888

Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India

Q44983136

Plasmodium vivax malaria in Duffy-negative individuals from Ethiopia

Q45728740

In vitro maturation of the exoerythrocytic stage of Plasmodium knowlesi observed under phase contrast microscopy

Q47883078

Radical curative activity of a new 8-aminoquinoline derivative (CDRI 80/53) against Plasmodium cynomolgi B in monkeys

Q47892158

Effect of certain drugs on exoerythrocytic parasites of Plasmodium cynomolgi.

Q47957686

THE SPECIES OF SIMIAN MALARIA: TAXONOMY, MORPHOLOGY, LIFE CYCLE, AND GEOGRAPHICAL DISTRIBUTION OF THE MONKEY SPECIES.

Q47960472

Appraisals of compounds of diverse chemical classes for capacities to cure infections with sporozoites of Plasmodium cynomolgi.

Q47988585

The 48-hour exoerythrocytic stage of Plasmodium cynomolgi bastianellii.

Q47990936

Observations on early and late post-sporozoite tissue stages in primate malaria. I. Discovery of a new latent form of Plasmodium cynomolgi (the hypnozoite), and failure to detect hepatic forms within the first 24 hours after infection

Q47993745

Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents

Q47994409

Demonstration of heat-shock protein 70 in the sporozoite stage of malaria parasites

Q48015403

In vitro culture of two populations (dividing and nondividing) of exoerythrocytic parasites of Plasmodium vivax

Q56487512

Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report

Q56525975

Relapses in primate malaria: discovery of two populations of exoerythrocytic stages. Preliminary note

Q71494290

High yield preparation of isolated human adult hepatocytes by enzymatic perfusion of the liver

Q72939538

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

Plasmodium cynomolgi

Q12505741

P304

page(s)

1586-1595

P577

publication date

2013-12-23

P1433

published in

Antimicrobial Agents and Chemotherapy

Q578004

P1476

title

KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro

P478

volume

Reverse relations

cites work (P2860)

Q48018710	A comparative transcriptomic analysis of replicating and dormant liver stages of the relapsing malaria parasite Plasmodium cynomolgi.
Q92465267	A dual fluorescent Plasmodium cynomolgi reporter line reveals in vitro malaria hypnozoite reactivation
Q27644391	A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria
Q33761137	A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance
Q27728080	A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor (DSM421) with improved drug-like properties for treatment and prevention of malaria
Q38658712	An improved Plasmodium cynomolgi genome assembly reveals an unexpected methyltransferase gene expansion
Q39337756	Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase.
Q45181102	Causal prophylactic efficacy of primaquine, tafenoquine, and atovaquone-proguanil against Plasmodium cynomolgi in a rhesus monkey model
Q36951722	Current therapies and future possibilities for drug development against liver-stage malaria
Q27861934	Diversity-oriented synthesis yields novel multistage antimalarial inhibitors
Q45968436	Drug discovery for the developing world: progress at the Novartis Institute for Tropical Diseases.
Q55278895	Drugs in Development for Malaria.
Q28542047	Evaluation of antimalarial activity and toxicity of a new primaquine prodrug
Q28829342	High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria
Q28081463	Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax
Q39633703	Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stages
Q28071293	Malaria modeling: In vitro stem cells vs in vivo models
Q38260909	New insight-guided approaches to detect, cure, prevent and eliminate malaria
Q36887985	PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites
Q38849773	Phenotypic Screens in Antimalarial Drug Discovery
Q38784765	Plasmodium knowlesi: a relevant, versatile experimental malaria model
Q92577757	Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stages
Q92391181	The antimalarial screening landscape-looking beyond the asexual blood stage
Q65937801	The liver-specific protein 2 (LISP2) is an early marker of liver stage development
Q61454598	Transcriptomic analysis reveals reduced transcriptional activity in the malaria parasite during progression into dormancy
Q56340021	UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria
Q47162062	malERA: An updated research agenda for basic science and enabling technologies in malaria elimination and eradication